We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Organoids Aid Discovery of New Approaches for Treating Pancreatic Cancer

By LabMedica International staff writers
Posted on 25 Jan 2015
Cancer researchers have established a method for culturing organoids from normal and cancerous mouse and human pancreatic tissues that is expected to boost development of personalized treatment approaches for this deadly disease.

Since pancreatic cancer is one of the most lethal malignancies due to its late diagnosis and limited response to treatment, methods to identify and study molecular pathways involved in tumor development are urgently needed. More...
Towards this end investigators at Cold Spring Harbor Laboratory (NY, USA) established organoid models from normal and cancerous mouse and human pancreas tissues. Pancreatic organoids could be rapidly generated from resected tumors and biopsies, survive cryopreservation, and exhibit ductal- and disease-stage-specific characteristics. Normal ductal cells that are able to develop into pancreatic cancer represent only about 10% of the cells in the pancreas, but the organoids were entirely composed of ductal cells, which eliminated surrounding cell types that often contaminate pancreatic samples.

Details published in the December 2014 online edition of the journal Cell revealed that the organoids were grown as hollow spheres within a complex gel-like substance filled with growth-inducing factors and connecting fibers. Once they had grown to a sufficient size, the organoids were transplanted into mice, where they fully recapitulated all the stages of pancreatic cancer development from early-grade neoplasms that progressed to locally invasive and metastatic carcinomas.

Due to their ability to be manipulated genetically, organoids served as an ideal platform to probe genetic cooperation. Comprehensive transcriptional and proteomic analyses of mouse pancreatic organoids revealed genes and pathways altered during disease progression. The confirmation of many of these protein changes in human tissues demonstrated that organoids were a useful model system to discover characteristics of this deadly malignancy.

“With this development, we are now able to culture both mouse and human organoids, providing a very powerful tool in our fight against pancreatic cancer,” said senior author Dr. David Tuveson, professor of pancreatic cancer medicine at Cold Spring Harbor Laboratory. “We hope to make this available to the entire pancreatic cancer research community.”

Related Links:

Cold Spring Harbor Laboratory



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.